We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Investors should focus on the science, setting aside market froth
DNA sequencing group expected to be valued at £4bn to £7bn in one of largest UK floats this year
Emma Stanton starts at Oxford Nanopore after contract ends at government programme
National inn chains suffer as new lockdown policy heralds more pub closures
There are plenty of discoveries to bring to market but domestic funding has been squeezed
UK biotech company hopes to challenge US dominance of gene sequencing market
Gene analysis group’s decision to list helps fund manager remain compliant with regulations
California-based group acquires 3 per cent stake in UK sequencing company
Fast-growing UK biotech will build factory to meet demand for gene sequencing machines
No laughing matter for minority investors
Investing in intellectual property commercialisation is not without risks
Independent directors should back a scheme of arrangement for benefit of investors
Oxford Nanopore announces new funding from Woodford Investment and HK-based investor
Oxford Nanopore received complaint over patent infringement of two-strand DNA sequencing
About 40% of WPC is in unquoted companies and two-thirds in healthcare
Accurately sequencing an individual’s DNA for less than $1,000 is now possible
The British scientist behind a pioneering DNA sequencer is plotting its international success
Start-ups tap homegrown capital rather than going stateside
Investment manager says UK sector deserves more financial support to prevent a brain drain to the US
Intellectual property is big business but finding funds is key
International Edition
